Pediatrix Medical Group, Inc. (NYSE:MD) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have received a consensus rating of “Hold” from the five analysts that are covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $16.10.

Several research firms have weighed in on MD. StockNews.com upgraded Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research note on Wednesday, November 13th. Deutsche Bank Aktiengesellschaft raised their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Jefferies Financial Group boosted their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. UBS Group increased their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, Mizuho lifted their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Monday, November 4th.

Insider Activity at Pediatrix Medical Group

In related news, CEO James D. Swift sold 11,100 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the sale, the chief executive officer now directly owns 170,001 shares in the company, valued at $1,834,310.79. This represents a 6.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the sale, the director now directly owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. The trade was a 16.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 53,808 shares of company stock worth $751,277 in the last quarter. 2.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Quest Partners LLC raised its stake in Pediatrix Medical Group by 25.6% during the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after buying an additional 622 shares during the last quarter. nVerses Capital LLC acquired a new stake in Pediatrix Medical Group during the 2nd quarter worth about $31,000. Innealta Capital LLC bought a new position in shares of Pediatrix Medical Group in the 2nd quarter worth about $33,000. Quarry LP lifted its stake in shares of Pediatrix Medical Group by 54.1% in the 3rd quarter. Quarry LP now owns 4,735 shares of the company’s stock valued at $55,000 after purchasing an additional 1,662 shares during the period. Finally, Nisa Investment Advisors LLC boosted its position in shares of Pediatrix Medical Group by 47.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after purchasing an additional 1,524 shares in the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Price Performance

NYSE:MD opened at $14.15 on Monday. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $16.41. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. The firm’s 50-day simple moving average is $12.53 and its 200 day simple moving average is $9.86. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -4.62, a P/E/G ratio of 2.03 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The firm had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The business’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the prior year, the company posted $0.29 earnings per share. As a group, sell-side analysts predict that Pediatrix Medical Group will post 1.25 earnings per share for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.